News

Patient treatment has been completed in a Phase 1/2 clinical trial testing cerebral dopamine neurotrophic factor (CDNF) for Parkinson’s disease, Herantis Pharma has announced. The trial (NCT03295786) is testing the safety and tolerability of CDNF in 17 patients with advanced Parkinson’s disease. Of these patients,…

A type of computational analysis that works to analyze typing patterns may help in detecting motor signs of Parkinson’s disease at early stages, the researchers who developed the analysis report. This new method, which appeared to allow researchers to discriminate between people with early Parkinson’s and those without the disease,…

The Feinstein Institutes for Medical Research announced that the U.S. Food and Drug Administration (FDA) has approved an imaging compound its researchers developed as a diagnostic tool for people with suspected parkinsonian syndromes, including Parkinson’s disease. Fluorodopa F18 (FDOPA) is an injectable compound used during a PET…

Parkinson’s News Today keeps you up-to-date with research into Parkinson’s disease as it emerges. We brought you daily coverage of experiments into the basic biology of Parkinson’s, results of clinical and pre-clinical trials, and key findings from Parkinson’s research around the globe. We look forward to bringing more such…

A Phase 1 clinical trial of MODAG Neuroscience Solutions’ lead candidate anle138b is now underway and recruiting healthy participants at its one site in Nottingham, England, to study the compound’s safety. The small molecule is being developed to treat multiple system atrophy (MSA), but holds the potential to…

Tasigna (nilotinib), an approved leukemia medication being tested as a repurposed treatment for Parkinson’s disease, was found to be safe and increased the levels of dopamine in the brain of patients with Parkinson’s disease, a Phase 2 trial shows. The findings were reported in a study, “Nilotinib…

Gosuranemab failed to meet its primary and key secondary goals in a Phase 2 study evaluating its use in treating progressive supranuclear palsy, an atypical parkinsonian disorder, its developer, Biogen, has announced. Based on these results, Biogen will cease the clinical development of gosuranemab for this and other neurodegenerative diseases…

Antibodies that selectively target the misfolded form of the alpha-synuclein protein — that which underlies the development of Parkinson’s disease — reduced the formation of alpha-synuclein clumps and improved dopamine levels in a mouse model.  The study with that finding also provided a framework for screening…

A new method allows researchers to develop adeno-associated virus (AVV) — commonly used as the vehicle for gene therapies — that accurately target and deliver genes to specific cells in the body. This new technology may be suitable to target dopaminergic neurons that are damaged in Parkinson’s disease. “We…

Sprint running is a safe and feasible form of physical exercise for people with mild-to-moderate Parkinson’s disease. That is the conclusion reached in the study, “Sprint exercise for subjects with mild-to-moderate Parkinson’s disease: Feasibility and biomechanical outputs,” was published in Clinical Biomechanics. Physical exercise has been…